Results 41 to 50 of about 3,490 (164)

The boosting effect of minoxidil 0.1% when combined with dutasteride 0.01% and microneedling in the treatment of female pattern hair loss

Journal of the Egyptian Women’s Dermatologic Society
Background Female pattern hair loss (FPHL) is a disease characterized by progressive hair thinning. Topical minoxidil is an FDA-approved drug for the treatment of androgenetic alopecia. Dutasteride (a 5α-reductase inhibitor) can also be used in a topical
Reham Essam, Heba Selim, Rana Ehab
doaj   +1 more source

Hyperpigmentation following Treatment of Frontal Fibrosing Alopecia

Case Reports in Dermatology, 2013
Introduction: Frontal fibrosing alopecia (FFA) is a scarring alopecia characterized by progressive recession of the frontotemporal hairline. Current treatment is aimed at stopping progression, and the combination of dutasteride and pimecrolimus is the ...
Irma Margarita Pérez-Rodríguez, Martha Elena García-Melendez, Kristian Eichelmann, Osvaldo Vázquez-Martínez, Jorge Ocampo-Candiani   +4 more
doaj   +1 more source

A Theoretical Model for the Treatment of Androgenetic Alopecia Using the STEAP3 Protein, and the Genetic Challenges of Treating AGA

Health Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background and Aims Androgenetic alopecia (AGA) is a prevalent condition. The treatment methods currently available for this condition have limited potential (minoxidil) and side effects with long‐term therapy that affect the physiology of the male population (5α‐reductase inhibitors).
Ignacy Klemens Młodzianowski, Małgorzata Grochocka, Tadeusz Tadrowski, Marta Hałas‐Wiśniewska, Magdalena Izdebska   +4 more
wiley   +1 more source

Integrating Prostate‐Specific Antigen Density and Prostate Imaging Reporting and Data System Scores to Optimize Detection of Clinically Significant Prostate Cancer: A Multivariable Risk Model Approach

Journal of Clinical Laboratory Analysis, Volume 40, Issue 12, June 2026.
For the detection of clinically significant prostate cancer, incorporating PSA density into PI‐RADS‐based assessment improved clinical net benefit compared with PI‐RADS alone. The addition of DRE and age to this combined model produced only marginal further gain, indicating that most of the incremental clinical value was derived from PSA density rather
Yunus Kayali
wiley   +1 more source

The role of dutasteride in reducing complications of transurethral resection of prostate [PDF]

Al Ameen Journal of Medical Sciences
Purpose: To evaluate the superiority of dutasteride over a placebo in patients having their prostate removed during transurethral resection for benign prostate hyperplasia. Material and Methods: The study included a total of 30 patients, with 15 patients
Shyamal Shah, P. Periasamy
doaj  

Advances in the Treatment of Androgenetic Alopecia: A Review of Mechanisms and the Clinical Efficacy of Combination Drug Therapy

Journal of Cosmetic Dermatology, Volume 25, Issue 6, June 2026.
ABSTRACT Background Androgenetic alopecia (AGA) is the most prevalent type of hair loss, exerting a significant negative impact on patients' quality of life. The limited efficacy, potential adverse effects, and poor patient adherence of single‐agent therapies highlight substantial unmet needs in clinical management.
Zhuhao Lai, Yi Zhou, Rui Zhou
wiley   +1 more source

Efficacy, safety, and adverse effects of finasteride and dutasteride in treating benign prostatic hyperplasia: A retrospective cohort study

Zanco Journal of Medical Sciences
Background and objective: Symptomatic benign prostatic hyperplasia (BPH) results in several symptoms including the lower urinary tract symptoms. Consequently, BPH may affect the bladder and finally the kidneys.
Wishyar Jamal Al-Bazzaz
doaj   +1 more source

Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer

Journal of Translational Medicine, 2023
Background The incidence of bladder cancer (BCa) is approximately four times higher in men than in women. To develop effective BCa treatments, there is an urgent need to understand the differences in the BCa control mechanisms based on gender. Our recent
Jaekwon Seok, Hee Jeong Kwak, Yeonjoo Kwak, Moonjung Lee, Kyoung Sik Park, Aram Kim, Ssang-Goo Cho   +6 more
doaj   +1 more source

Quality of Life in Men Treated for Androgenetic Alopecia via a Digital Healthcare Platform: A Retrospective Cohort Study

Journal of Cosmetic Dermatology, Volume 25, Issue 6, June 2026.
ABSTRACT Background Androgenetic alopecia (AGA) is a common chronic condition significantly impacting quality of life (QoL), but few studies have explored treatment outcomes in real‐world digital health settings. Aims The objective of this study is to evaluate the effects of AGA treatment delivered through a digital healthcare platform on patient ...
Angela C. Bersch‐Ferreira, Daniel Reisel, Ashley K. Clift, John C. T. Chao, Hans Johnson, David R. Huang, Hudson Dutra, Gabriel Guimarães   +7 more
wiley   +1 more source

Probing the Biological Plausibility of Fluoride as an Endocrine Disruptor

Birth Defects Research, Volume 118, Issue 5, May 2026.
ABSTRACT Background Fluoride has come under recent scrutiny regarding concerns over potential neurodevelopmental and endocrine‐related toxicities, with recent reviews by the National Toxicology Program (NTP) and European Food Safety Authority (EFSA) concluding with moderate or reasonable confidence, respectively, that exposure to drinking water having ...
Ashley M. Mudd, Bladimir J. Ovando, George P. Daston   +2 more
wiley   +1 more source